High-Dose Chemotherapy for Non-Hodgkin's Lymphoma
Author Information
Author(s): P Pronzato, R Lionetto, F Botto, F Pensal, A Tognoni
Primary Institution: Ospedale S. Andrea, La Spezia, Italy; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Hypothesis
Can the acceleration of chemotherapy cycles improve dose intensity in non-Hodgkin's lymphoma treatment?
Conclusion
The study demonstrated that accelerating chemotherapy cycles is feasible and can achieve the desired dose intensity without excessive toxicity.
Supporting Evidence
- Eighteen out of twenty patients achieved the planned dose intensity.
- Fifteen patients had objective responses, including eight complete responses.
- Median survival for all patients was 24 months.
Takeaway
Doctors gave a special treatment to 20 people with a type of cancer to see if they could give stronger medicine more often without making them too sick, and it worked well.
Methodology
Patients received a combination of chemotherapy drugs every 14 days, with G-CSF support to help manage side effects.
Limitations
The study was limited by its small sample size and the lack of a control group.
Participant Demographics
Patients had intermediate- to high-grade non-Hodgkin's lymphoma, with a median age of 66 years.
Want to read the original?
Access the complete publication on the publisher's website